X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
To assess efficacy and safety of oral X-396 (Ensartinib) capsule in Chinese ALK-positive
NSCLC patients with brain metastases, eligible patients will be enrolled with objective
responses being primary outcome measures.